🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great effort! OncoAlert

Very good and balanced discussion by Dr. Krop today. Hopefully we will get the approval extension soon so that we can individualize treatment with TDXd in HER2-low MBC like he suggested in his algorithm OncoAlert

WSG proudly presents the ADAPT HER2 IV trial. Already 36 patients enrolled in this neoadjuvant deescalation trial with TDXd in HER2+ EBC. @dkatesharbeck OncoAlert

Fantastic news for patients! OncoAlert

It’s a privilege to wrap up #ASCO24 for our patients Renate Haidinger #OncoAlert

Fantastic #ASCO24 great connecting again. Hope everyone got home safe. See you all at #ESMO in Barcelona #OncoAlert

Please don’t forget to join us today Wednesday June 5 6:30 pm CEST for another #myESMO breast cancer deep dive webinar #oncoalert

Congratulations Felix Feng for this well deserved @ASTRO Award. Such a privilege to be working on amazing science together with Felix. #OncoAlert

Great discussion last night on personalized prevention and detection of breast cancer. You can still watch it on demand and collect points towards your #myESMO certificate of professional development. #OncoAlert

Couldn’t agree more. Fantastic work by #myriamChalabi and colleagues #Oncoalert

Dear Colleagues, The ESMO - Eur. Oncology Presidential Elections are going on LAST Day to VOTE is June 10th (noon CET) REMINDER THAT ALL VOTES ARE CONFIDENTIAL & NO ONE CAN SEE WHO YOU VOTE FOR esmo.org/about-esmo/how… Election Security is something ESMO takes very seriously to have a FAIR

Glad Kathrin Carl P. Heinrich views us this way. The purpose of a role model should be to help others grow and advance themselves by positive support and encouragement #OncoAlert

Chairing an Oxford discussion on Ki67 at the Annual German Senology Conference. Amazing to see that about 70% of the breast centers use endocrine response assessment in clinical routine according to WSG ADAPT. #OncoAlert

Welcome to Munich #myESMOGI24 looking forward to an exciting. Scientific exchange #OncoAlert

Hope everyone had a nice summer. Thanks so much to all of you supporting my presidential campaign earlier this year. Proud to continue serving #myESMO as director of education. Looking forward to #ESMO2024 starting tomorrow. See you all there #oncoalert

#ESMO2024 has officially started. Rebecca dent outlineing that multidisciplinary collaboration will advance the field of oncology #oncoalert

Congratulations to all #ESMO2024 awardees for their awards honoring their outstanding and visionary research #oncoalert

Miguel Martin presented Independent validation of TNBC-DX at #ESMO2024 it significantly predicted pCR and outcome in early TNBC #OncoAlert

Oleg Gluz from WSG at #ESMO2024 showed excellent outcome results from WSG TP-2 trial in HER2+ HR+ EBC after 12-week deescalated neoadjuvant paclitaxel or endocrine therapy, both arms with Trastuzumab and oertuzumab for 1y. #OncoAlert

S. Kümmel presented final data from WSG ADAPT HR+ HER2-. Similar survival between dose-dense taxane regimens using nab-paclitaxel or packitaxel and anthraclines. Patients with N0-1 RS <26 and endocrine response hat excellent 5yr ddfs >96% with endocrine therapy alone. #OncoAlert